Non-invasive visual tools for diagnosis of oral cancer and dysplasia: A systematic review

Ilaria Giovannacci ¹, Paolo Vescovi ¹, Maddalena Manfredi ², Marco Meleti ²

¹ DDS, Msci. Department of Biomedical, Biotechnological and Translational Science-Center of Oral Laser Surgery and Oral Pathology, Dental School, University of Parma, Parma, Italy
² DDS, PhD. Department of Biomedical, Biotechnological and Translational Science-Center of Oral Laser Surgery and Oral Pathology, Dental School, University of Parma, Parma, Italy

Correspondence:
Center of Oral Laser Surgery and Oral Medicine
Dental School. Department of Biomedical Biotechnological and Translational Sciences
Via Gramsci, 14 - 43125 Parma, Italy
marco.meleti@unipr.it

Received: 11/08/2015
Accepted: 14/10/2015

Abstract
Background: Gold standard for the diagnosis of oral dysplasia (OD) oral squamous cell carcinoma (OSCC) and malignant lesions is the histological examination. Several adjunctive diagnostic techniques have been proposed in order to increase the sensitivity (SE) and specificity (SP) of conventional oral examination and to improve the diagnostic first level accuracy. The aim of this study is to perform a systematic review on non-invasive tools for diagnosis of OD and early OSCC.

Material and Methods: Medline, Scopus, Web of Knowledge databases were searched, using as entry terms “oral dysplasia AND diagnosis” / “oral cancer AND diagnosis”. Data extracted from each study included number of lesions evaluated, histopathological diagnosis, SE, SP, positive and negative predictive values (PPV and NPV), diagnostic accuracy (DA) and the main conclusions.

Results: After title and abstract scanning of 11,080 records, we selected 35 articles for full text evaluation. Most evaluated tools were autofluorescence (AF), chemiluminescence (CL), toluidine blu (TL) and chemiluminescence associated with toluidine blue (CLTB).

Conclusions: There is a great inhomogeneity of the reported values and there is no significant evidence of superiority of one tool over the other. Further clinical trials with a higher level of evidence are necessary in order to assess the real usefulness visual diagnostic tools.

Key words: Oral dysplasia, oral cancer, diagnosis, visual diagnostic tool, systematic review.
Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most common malignant tumour, with an incidence of more than 500,000 cases per year (1). The most important prognostic factor influencing the disease-specific survival rate is the tumour stage at diagnosis. Patients with stage I tumours have a 5-year survival rate of 75%, which dramatically decreases in patients with tumours in stage III or IV, being 49% and 30%, respectively (1,2).

The diagnostic pathway for oral suspicious lesions usually starts with the conventional objective examination (COE) based on inspection and palpation of the oral mucosa with the support of an incandescent light available on the dental chair. It is well known that COE mainly depends on a subjective interpretation, which is a consequence of the experience of the operator. Moreover, oral epithelial dysplasia (OED) and early OSCC may already be present within areas of oral mucosa macroscopically normal, as well as within the context of oral potentially malignant disorders such as leukoplakia, erythroplakia, submucous fibrosis and oral lichen planus (3). The gold standard for the diagnosis of oral dysplastic and neoplastic malignant lesions is the histological examination (4). Incisional or excisional biopsy techniques are the most reliable methods to collect a surgical specimen suitable for microscopic evaluation. However, despite the little invasiveness of such techniques, they still have some disadvantages in terms of morbidity and possible artifacts induced by the method of collection.

In a recent paper, Mehrotra et al. indicated that there are two approaches for detection of oral dysplasia and cancer: 1) oral cancer screening programs that identify asymptomatic patients with suspicious lesions and 2) specific diagnostic tools to identify dysplasia and early oral cancers in asymptomatic patients with an oral abnormality (5). Several visual diagnostic aids have been developed as adjunctive tools in order to increase the diagnostic accuracy (DA) and enhance the specificity (SP) and sensitivity (SE) of the conventional diagnostic pathway. However, results of studies on the usefulness of such tools show impressive discrepancies with regard to values such as the positive or negative predictive values (PPV, NPV), when the same tools are evaluated by different researchers.

The aim of this study is to perform a systematic review on non-invasive tools for the diagnosis of OED and OSCC, taking into account factors as SE, SP, PPV, NPV and DA.

Material and Methods
The databases Medline, Scopus and Web of Knowledge were searched, using as entry terms “oral dysplasia AND diagnosis” / “oral cancer AND diagnosis”. No time limits were specified in the present research.

Search flow is shown in figure 1. Papers with abstract unavailable were excluded for further evaluation. Titles and abstract were screened and the following exclusion criteria were applied:
- papers not in English.
- studies ex vivo or based on animal models.
- typology of the study: case reports, case series with less than 10 patients, conference proceedings, personal communications, editorials, descriptive studies and reviews.
- studies that analyse COE, invasive diagnostic tools (e.g. scalpel biopsy) or minimally invasive diagnostic tools (e.g. brush biopsy, exfoliative cytology) alone.
- studies that analyse salivary biomarkers.
- studies including also tumours of other head and neck regions (e.g. oropharynx).

Papers with equivocal abstracts were included for full-text evaluation. Further studies were excluded after full-text reading, if not pertinent with aim of the present review.

Data extracted from each study included authors and publication year, typology of the study, diagnostic tool analysed, number of lesions evaluated, if present histopathological diagnosis, (if present) SE, SP, PPV, NPV, DA and the main conclusions of the study (Tables 1 and 1 continue).2).

SE and SP measure the accuracy of a test without any relation to the disease or population, whereas PPV and NPV measure the proportion of people whose test results reflect their health status. DA is the proportion of true positive results (both true positive and true negative) in a selected population, with regard to a specific disease. The mean value of each variable analysed was calculated; range and standard deviation (SD) were indicated for samples having > 2 values.

Level of evidence of each study was assessed according to the Oxford Evidence-based Medicine (OEBM) Levels for Diagnosis updated in March 2009.

Results
Twenty-three papers were eventually selected for the present systematic review when using “oral dysplasia AND diagnosis” as entry terms. The use of “oral cancer AND diagnosis” as entry terms allowed the identification of further 25 full-text manuscripts (6-39).

Twenty-three studies were perspective (OEBM level: 2b), 4 studies were pilot (OEBM level: 3b), 3 studies were case-control (OEBM level: 4), 4 studies were cross-sectional (OEBM level: 2b). Only one study was a prospective randomized clinical trial (RCT) (OEBM level: 1b).

Eight typologies of non-invasive visual diagnostic tools were identified (Table 3). Mean SE and SP (with SD) are shown in figures 2,3.

1. Auto fluorescence (AF) - Direct visual fluorescence examination (DVFE)
Among 12 studies evaluating AF/DVFE, 8 were perspective (OEBM level: 2b), 2 were cross-sectional (OEBM level: 3b) and 1 was a pilot study (OEBM level: 1b) (6,10,13,14,16,18,24,29,32,33,35).

Data on SE were reported in 10 studies, while information on SP was available in 11 studies. Mean SE was 72.4% ranging from 20% to 100% (SD = 27.1). Mean SP was 63.79% ranging from 15.3% to 100% (SD = 28.17). Data on PPV were available in 5 studies (mean: 55.74%, ranging from 15.1% to 92%, SD = 36.71); data on NPV were available in 5 studies (mean: 79.76%, ranging from 61% to 100%, SD = 15.99); DA was reported in 1 study (55%).

2. Chemiluminescence (CL)

Among 5 studies evaluating CL, 4 were perspective (OEBM level: 2b) and 1 was observational cross-sectional (OEBM level: 2b) (7,15,38).

Data on SE and SP were reported in 4 studies. Mean SE was 86.72%, ranging from 69.6% to 100% (SD = 15.65).
| No | Authors and year (ref) | Typology of the study | Diagnostic tools analysed | Number of lesions | Histopathologic diagnosis | Results | Main authors conclusions |
|----|------------------------|-----------------------|--------------------------|------------------|---------------------------|---------|------------------------|
| 1  | Petruzzi M et al. 2014 (6) | Double centre cross sectional study | DVFE vs TB | 56 | NS | DVFE: SE: 70%, SP: 57.7%, PPV: 65.6%, NPV: 70.6% (mild dysplasia positive) | DVFE and TB are both sensitive but not specific in OSCC and dysplasia diagnosis. |
| 2  | Kämmerer PW et al. 2013 (7) | Perspective study | CL; CLTB | 50 | Reactive lesions (40), dysplastic lesions (3), OSCC (7) | CL: SE: 100%, SP: 30%, PPV: 26%, NPV: 100% | The adjunct of TB to CL reduces the number of false positives without increasing the rate of false negatives. |
| 3  | Pallagatti et al. 2013 (8) | Perspective study | TB | 37 | Benign lesions (14), dysplastic lesions (23) | SE: 95%, SP: 71.45%, PPV: 84.6%, NPV: 90.9%, DA: 86.48% | The use of TB staining was taken into consideration to identify clinically doubtful oro-pharyngeal lesions. |
| 4  | Mital et al. 2012 (9) | Pilot study | BR | 20 | Dysplastic lesions (17), Verrucous Ca (1), OSCC (3) | SE and DA: 90% | BR staining can be used as a valuable diagnostic test in the detection of oral potentially malignant and malignant disorders. |
| 5  | McNamara KK et al. 2012 (10) | Perspective study | DVFE vs COE | 95 | Benign lesions (50), premalignant lesions (2), malignant (1) – 52 no f/u | DVFE was statistically different from scalpel biopsy (P=0.0001) | COE is more valid than DVFE at discriminating benign mucosal alterations from premalignancy and do not support the use of DVFE as oral cancer screening adjunct. |
| 6  | Awan KH et al. 2012 (11) | Perspective study | TB | 92 | Benign lesions (51), Dysplastic lesions (41) | SE: 56.1%, SP: 56.9% | TB is a useful adjunct to clinical visual examination by aiding in the visualization of lesions. |
| 7  | Mojsa et al. 2012 (12) | Perspective study | CLTB | 41 | Benign lesions (34), Dysplastic lesions (6), OSCC (1) | SE: 81.8%, SP: 37.5%, PPV: 84.4%, NPV: 33.3% | CLTB may help to visualize oral pathologic lesions that are not readily detectable with conventional operatory lighting. |
| 8  | Farah et al. 2011 (13) | Perspective study | DVFE | 118 | Non dysplastic lesions (91), dysplastic lesions (24), OSCC (3) | SE: 30%, SP: 63%, PPV: 19%, NPV: 75%, DA: 55% | DVFE cannot provide a definitive diagnosis regarding the presence of epithelial dysplasia. |
| 9  | Paderni C et al. 2011 (14) | Perspective study | DVFE | 175 | Benign lesions, dysplastic lesions, OSCC | SE (OSCC): 96.4%, dysplasia (60%), no dysplasia (71%) | The device was found to not replace the histopathology procedure. However, it is useful for oral tissue examination. |
| 10 | Awan KH et al. 2011 (15) | Perspective study | CL | 126 | Non dysplastic lesions (82), dysplastic lesions (44) | SE: 77.3%, SP: 27.8% | CL does not have the ability to accurately classify PMD by discriminating between high-risk and low-risk lesions and therefore should be used with caution. |
| 11 | Awan KH et al. 2011 (16) | Perspective study | DVFE | 126 | Non dysplastic lesions (82), dysplastic lesions (44) | SE: 84.1%, SP: 15.3% | The device was unable to discriminate high-risk from low-risk lesions. |
| 12 | Moro A et al. 2010 (17) | Perspective study | DVFE | 32 | Non dysplastic lesions (20), dysplastic lesions (6), OSCC (6) | SE: 100%, SP: 95%, PPV: 92%, NPV: 100% | Preliminary results seem to indicate that autofluorescence is a high-performing test for the individualization of oral cancer in populations at risk. |
Studies identified using as entry terms “oral dysplasia AND diagnosis”.

| Study | Design | Methodology | Lesions | SE | SP | PPV | Notes |
|-------|--------|-------------|---------|----|----|-----|-------|
| Koch FP et al. 2010 (18) | Perspective blinded CT | DVFE | 78 | Non dysplastic lesions, dysplastic lesions, OSCC | SE: 20%, SP: 98%, PPV: 87%, NPV: 61% (OSCC/dysplasia) | Red autofluorescence should be an indication for scalpel biopsy due to a high PPV for cancer. |
| Sieroh A et al. 2008 (19) | Perspective study | LIFE | 14 | Inflammatory lesions, dysplastic lesions, OSCC | This study demonstrates a dependence of numerical color value (NCV) on histopathological grade | Diagnostics using white-light imaging with LIFE imaging is not only a significant faster method and a better diagnostics of pre-neoplastic and neoplastic lesions, but also there is a correlation between NCV and histopathological grade. |
| Schwarz RA et al. 2009 (20) | Case-control study | DSOS | 154 | Non dysplastic lesions (66), dysplastic lesions (44), OSCC (44) | SE and SP comparable to expert COE | DSOS has potential to augment oral cancer screening efforts in community settings. |
| Mallia RJ et al. 2008 (21) | Case-control study | LIFE | 44 | Hyperplastic lesions, dysplastic lesions, OSCC | SE: 100%, SP: 96% (hyperplastic vs dysplastic) SE: 95%, SP: 86% (dysplastic vs OSCC) | This methodology could act as an adjunct for early discrimination of oral dysplasias and hyperplasias. |
| Epstein JB et al. 2007 (22) | Perspective study | CLTB | 97 | Non dysplastic lesions (43), dysplastic lesions (41), OSCC (13) | SP: 55.26%, NPV: 100% | The results suggest that use of this technology will facilitate identification of oral mucosal lesions that require follow-up |
| Du GF et al. 2007 (23) | Pilot study | BR | 128 | Non dysplastic lesions (95), dysplastic lesions/OSCC (33) | SE: 93.9%, SP: 73.7% | BR staining may be a valuable diagnostic test in detection of PMD and malignant lesions. |
| Lane PM et al. 2006 (24) | Pilot study | DVFE | 44 | NS | SE: 98%, SP: 100% | This device is a suitable adjunct for oral cancer screening, biopsy guidance and margin delineation. |
| Sharwani A et al. 2006 (25) | Perspective study | ESS | 25 | Non dysplastic lesions (14), dysplastic lesions (10), OSCC (1) | SE: 72%, SP: 75% | ESS may be able to identify dysplasia in oral tissues. |
| Onofre MA et al. 2001 (26) | Perspective study | TB | 50 | Non dysplastic lesions (37), dysplastic lesions (6), OSCC (7) | SE: 77%, SP: 67%, PPV: 43.5%, NPV: 88.9% | TB staining is an adjunct to clinical judgment and not a substitute for either judgment or biopsy. |
| Leunig A et al. 2000 (27) | Perspective study | 5-ALA induced PPIX fluorescence | 58 | NS | SE: 99%, SP: 60% | PPIX could represent a possible new diagnostic tool to detect early malignant and secondary lesions in the oral cavity. |
| Martin IC et al. 1999 (28) | Perspective study | TB | 14 | Dysplastic lesions/OSCC | False negative rates: 42% (Ca in situ), 58% (moderate dysplasia) | This study suggests restricting the use of TB in high-risk patients and in cases of suspicious oral lesions. |

Abbreviations: BR=Bengal Rose; CL=Chemiluminescence; Chemiluminescence associated with Toluidine Blue (CLTB); COE=conventional objective examination; DA=diagnostic accuracy; DSOS=depth-sensitive optical spectroscopy; DVFE=direct visual fluorescence examination; ESS=elastic scattering spectroscopy; LIFE=laser induced fluorescence examination; NPV=negative prognostic value; NS=not specified; OSCC=oral squamous cell carcinoma; PMD=potentially malignant disorders; PPV=positive prognostic value; PPIX=protoporphyrin IX; SE=sensitivity; SP=specificity; TB=toluidine blue; 5-ALA=5-aminolevulinic acid.
Table 2. Studies identified using as entry terms “oral cancer AND diagnosis”.

| No | Authors and year (ref) | Typology of the study | Diagnostic tools analysed | Number of lesions | Histopathologic diagnosis | Results | Main authors conclusions |
|----|------------------------|-----------------------|--------------------------|-------------------|--------------------------|---------|-------------------------|
| 1  | Bhatia N et al 2014 (29) | Perspective study     | DVFE                     | 222               | NS                       | SE: 64%, SP: 54.3%, PPV: 15.1%, NPV: 92.2% | DVFE may aid in the detection of dysplasia which may not be identified by COE alone |
| 2  | Francisco AL et al 2014 (30) | Case-control study   | FS                       | 116               | Non dysplastic lesions (NS), dysplastic lesions (NS), OSCC (55) | SE: 93.8%, SP: 88.5% | FS is an important tool for oral cancer and PMD diagnosis. |
| 3  | Guze K et al. 2014 (31)  | Pilot study           | RS                       | 18                | Non dysplastic lesions (4), dysplastic lesions (3) OSCC (11) | SE: 100%, SP: 77% | RS offers the potential to provide point of care diagnosis of oral disease using a non-invasive, convenient, and relatively inexpensive technology. |
| 4  | Hanken H et al. 2013 (32) | Perspective, single-blinded study | DVFE                     | 60                | Non dysplastic lesions (12), dysplastic lesions (47) OSCC (1) | SE: 97.9%, SP: 41.7% (DVFE+COE), SE: 75.9%, SP: 33.3% (COE) | DVFE is a simple, non-invasive test of the oral mucosa that can help the experienced clinician to find oral premalignant lesions. |
| 5  | Rana M et al. 2012 (33) | Perspective randomized study | DVFE                     | 123               | NS                       | SE: 100%, SP: 74% (DVFE+COE), SE: 17%, SP: 97% (COE) | DVFE is a useful device for detection of oral cancer. |
| 6  | Sharma N et al. 2011*  | Observational, cross-sectional study | CL vs TB                 | 50                | NS                       | TB – SE: 56.6%, SP: 71.4%, PPV: 65%, NPV: 66.7%, CL – SE: 69.6%, SP: 81.5%, PPV: 76.2%, NPV: 35.9% | Accuracy, sensitivity, predictive values of TB is superior to exfoliative cytology. Role of CL in detecting dysplasia was slightly superior but comparable to TB. |
| 7  | Cancela-Rodríguez P et al. 2011 (34) | Perspective study | TB                       | 160               | Non dysplastic lesions (131), dysplastic lesions (16) OSCC (13) | SE: 65.5%, SP: 73.3%, PPV: 35.2%, NPV: 90.6% | The test can be a valuable adjunct to the diagnostic process, as long as it is carefully correlated with the clinical characteristics of the lesion and histopathological diagnosis. |
| 8  | Mehrotra R et al. 2010 (35) | Cross-sectional study | CLTB; DVFE               | 102 (CLTB); 156 (DVFE) | CLTB - Non dysplastic lesions (98), dysplastic lesions (3) OSCC (1) DVFE - Non dysplastic lesions (144), dysplastic lesions (11) OSCC (1) | CLTB - SE: 0%, SP: 75.5% DVFE - SE: 90%, SP: 38.9% | The study results indicate that use of CLTB or DVFE along with a COE for lesions deemed clinically innocuous was not beneficial in identifying dysplasia or cancer. |
| 9  | Oh ES et al. 2007 (36) | Perspective study   | CL                       | 95                | NS                       | No additional lesions were detected with CL. | The overall detection rate was not significantly improved. |
| 10 | Chen YW et al. 2006 (37) | Prospective study | MB                       | 58                | Non dysplastic lesions (29), dysplastic lesions (13), OSCC (16) | SE: 90%, SP: 69.6%, PPV: 74%, NPV: 84% | MB staining may be useful as a screening tool for oral cancer in large, high-risk groups in a similar way to the more expensive TB. |
| 11 | Ram S et al. 2005 (38) | Perspective study | CL and TB                | 31                | Non dysplastic lesions (7), dysplastic lesions (10) OSCC (14) | CL - SE: 100%, SP: 14.2%, DA: 80.6% TB - SE: 70.3%, SP: 25%, DA: 64.5% | CL is a more reliable diagnostic tool than TB in the detection of oral cancer and PMD. |
| 12 | Warnakulasuriya et al. 1996 (39) | Perspective study | TB                       | 145               | Non dysplastic lesions (88), dysplastic lesions (59) OSCC (18) | SE 100% (OSCC), 79.5% (dysplasia) SP: 62% | TB is valuable for surveillance of high-risk subjects in addition to its remarkable sensitivity in the detection of invasive carcinoma. |

Abbreviations (not included in Table 1): FS=fluorescence spectroscopy; MB=methylene blue. * Reference Scopus indexed (Sharma N, Mubeen. Non invasive diagnostic tools in early detection of oral epithelial dysplasia. J Clin Exp Dent. 2011;3(3):e184-8.)
Mean SP was 38.37%, ranging from 14.2% to 81.5% (SD = 29.59).

Data on PPV and NPV were available in 2 studies (mean PPV: 74.5%; mean NPV: 63%); DA was reported in 1 study (80.6%).

3. Toluidine Blue (TB)
Among 9 studies evaluating TB, 7 were perspective (OEBM level: 2b) and 2 were cross-sectional (1 perspective cross-sectional and 1 observational cross-sectional) (OEBM level: 2b) (6, 8, 11, 26, 28, 34, 38, 39).

Data on SE and SP were available in 8 studies. Mean SE resulted 72.5%, ranging from 56.1% to 95% (SD = 13.13). Mean SP resulted 61.4%, ranging from 25% to 74.1% (SD = 15.95).

Data on PPV were available in 5 studies (mean: 56.1%, ranging from 35.2% to 84.6%, SD=19.4); data on NPV were available in 5 studies (mean: 95.3%, ranging from 66.7% to 90.9%, SD=11.42); data on DA were available in 2 studies (mean: 75.49%).

A perspective study evaluating Methylene Blue (MB) was also identified. In this study SE (90%), SP (69%), PPV (74%) and NPV (84%) were available (37).

4. Chemiluminescence associated with Toluidine Blue (CLTB)
Among 4 studies evaluating CLTB, 3 were perspective (OEBM level: 2b) and 1 was cross-sectional (OEBM level: 2b) (7, 12, 22, 35).

Data on SE were available in 3 studies, while data on SP were available in 4 studies. Mean SE was 53.93%, ranging from 0% to 81.8% (SD = 46.72). Mean SP was 66.44%, ranging from 37.5% to 97.5% (SD=25.88).

Data on PPV were available in 2 studies (mean: 87.2%); data on NPV was available in 3 studies (mean: 76.1%, ranging from 33.3% to 100%). DA was not reported in any study.

5. Bengal Rose (BR)
The 2 studies evaluating BR were pilot studies (OEBM level: 3b) (9, 23).
Data on SE were available in both the papers (mean: 91.95%); mean SP was available in 1 study (73.7%). Data on PPV and NPV were not available in any study, while DA was reported in 1 study (DA: 90%).

6. Laser-induced fluorescence examination (LIFE)
Among the 2 studies evaluating LIFE, 1 was perspective and 1 was a case-control study (OEBM level: 2b and 4, respectively) (19,21).
Data on SE and SP were available in 1 study. SE ranged from 100% to 95% and SP ranged from 96% to 86% taking into account the histopathological diagnosis.
Data on PPV, NPV and DA were not reported in any study.

7. 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) fluorescence
Only one perspective study evaluating this tool was included in the present research (OEBM level: 2b) (27).
SE was 99%; SP was 60%. Data on PPV, NPV and DA were not available.

8. Optical spectroscopy
One case-control study regarding fluorescence spectroscopy (FS), one pilot study regarding Raman spectroscopy (RS), one perspective study regarding Elastic scattering spectroscopy (ESS) and one case-control study regarding an experimental assessment of depth-sensitive optical spectroscopy (DSOS) were identified (OEBM level: 4, 3b, 2b and 4, respectively) (20,25,30,31).
Among these, SE and SP were available for FS (SE: 93.8%, SP: 88.5%), RS (SE: 100%, SP: 77%) and ESS (SE: 72%, SP: 75%) (25,30,31).
Data on PPV, NPV and DA were not available in any study.

Discussion
The principles of functioning of non-invasive visual diagnostic tools for OSCC and dysplastic lesions are very different, being based on diverse specific cellular and tissue characteristics. Such a great diversity may partly explain the impressive discrepancy of results obtained in the studies analysed. Another reason which can give some reasons for the wide range of results, in terms of SE, SP and DA is the great variability both of the typology of the studied lesions and of the diagnostic criteria used for the clinical and histological assessment of such lesions. The difficulty to establish univocal and broadly-accepted criteria for the assessment of the OED has been widely reported, particularly, with regard to the inter- and intra-observer disagreement for the diagnosis. Moreover, SE and SP may well depend on the degree of development of a lesion, seeming quite reasonable that both these indicators increase with the progression of a lesion from normal, to dysplastic, early neoplastic and invasive and destructive lesion.
Taking into account the abovementioned considerations, we report a short discussion for each tool analysed:
- Auto fluorescence (AF) - Direct visual fluorescence examination (DVFE)
Auto fluorescence (AF) uses natural fluochromes which are located within the epithelium and the submucosa and which are excited when irradiated with specific wavelengths. Using wavelengths between 375 and 440 nm, some fluochromes show fluorescence in the range of the green colour. Following such irradiation, normal, unaltered mucosa emits a pale green AF light when viewed through a selective, narrow-band filter. A
proper filtration is crucial, due to the intense light used for excitation of the fluorochromes (13,15). Areas of reduced AF (dark areas) are suspicious for epithelial dysplasia or OSCC, whereas normal mucosa appears bright green (10).

The VELscope™ (LED Medical Diagnostics Inc., Barnaby, Canada) system consists of a non-invasive device designed to visualise early mucosal changes using the principles of tissue AF. According to such principles, dysplastic changes should be associated with a loss of stromal AF (29,32). It seems of paramount importance to highlight here that benign lesions, or those associated to inflammation, can also be characterized by a loss of stromal AF, which grossly limits the diagnostic specificity, especially in low-risk populations.

Mean SE and SP for this tool, were 72.4% and 63.79%, respectively. It is opinion of the authors that such values, at the moment, are unacceptable for a tool specifically dedicated to the diagnosis of oral mucosal malignant lesions. However, it should be stressed that there are apparently no other non-invasive visual diagnostic tools significantly better than AF-based tools.

It is somewhat surprising that values of SE range from 20% to 100% and value of SP goes from 15.3% to 100%.

Level of EBM for the selected studies seem to be quite acceptable, being ≥ 2b for all the studies, except one (3b level) (24). It is worthy mentioning that the study with the highest EBM level (1b) showed high values both of SE and SP (100% and 74%, respectively) (33).

- Chemiluminescence (CL)

The ViziLite® (VL - Zila Pharmaceuticals, Phoenix, AZ) was the first FDA-approved (2002) adjunctive technology to conventional head and neck examination for improving visualization of early dysplastic or neoplastic lesions. This system involves an oral rinse with a 1% acetic acid solution for 1 minute, to remove the glycoprotein barrier and slightly desiccate the oral mucosa. A diffuse chemiluminescent blue/white light with an average wavelength of 490 to 510 nm is then activated and used to examine the oral tissues. Normal cells absorb the light and appear blue, whereas abnormal cells have a higher nuclear/cytoplasmic ratio and should reflect the light appearing whiter with brighter, sharper, more distinct margins (15,36,38).

Mean SE and SP resulted 86.72% and 38.37%, respectively. All the analysed studies have an EBM level of 2b, but there is a great inhomogeneity especially for SP, which ranges from 14.2% to 81.5%.

- Toluidine Blue (TB)

Toluidine blue (TB), also known by its chemical name tolunium chloride (TC), is a cationic met achromatic dye that may selectively bind to free anionic groups such as sulfate, phosphate, and carboxylate radicals of large molecules. It has been used for decades as aid to the identification of mucosal abnormalities of the cervix as well as those in the oral cavity (8).

TB stains deoxyribonucleic acid and/or may be retained in intracellular spaces of dysplastic epithelium, which clinically appears as royal blue areas. It is postulated that the increased amount of DNA and RNA in neoplastic cells and the wider intercellular canals compared to normal epithelial cells are responsible for staining malignant cells (11).

Mean SE and SP were 72.5% and 61.4%, respectively. These values are poorly acceptable in oncologic diagnosis and they seem to be more realistic because standard deviations are lower than those calculated for the other diagnostic tools.

- Chemiluminescence associated with Toluidine Blue (CLTB)

In order to reduce the high number of false positive cases obtained through VL, the manufacturer added TB (ViziLite Plus® - VLP) (12,22).

Data related to the use of this technique are very poor and discordant; mean SE and SP were 53.93% and 66.44%, respectively, but standard deviations were excessively high.

- Rose Bengal (RB)

Rose Bengal (RB) is the 4,5,6,7-tetrachloro- 2',4',5',7'-tetraiodo-derivative of fluorescein. It has been widely used to diagnose various ocular surface disorders. It has been believed to stain desquamated ocular epithelial cells, dead or degenerated cells but not healthy epithelial cells. RB staining was even used to delineate the extent of corneal and conjunctival neoplasms. Therefore, such findings of RB enlightened us to carry out researches in detection of oral preneoplastic and malignant lesions (9,23).

Data on SE and SP related to this tool are scarce and resulting from studies of low OEBM level (3b).

- Laser-induced fluorescence examination (LIFE)

This technique is based on AF of the tissue as well as DVFE. The instrumentation proposed by Mallia et al. is comprised of a diode laser (Stocker Yale, Canada, 404 nm, 50 mW, CW) for excitation of tissue fluorophores (21). Light emission from the laser source is guided to the oral mucosa through a 3 µm long bifurcated fiber optic probe that has a central fiber to deliver the excitation beam and 6 surrounding fibers (400 µm diameter each) to collect AF emissions. The red to green colour ratio is defined as the numerical color value (NCV).

Two studies regarding this tool have been selected for this review. SE and SP values are reported in 1 study only and they are high (SE: 100%-95%; SP: 96%-86%, according to the histopathological diagnosis), but the OEBM level is low (4). Data from further studies with a higher OEBM level are necessary.

- 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) fluorescence
Only one perspective study describing this technique was selected for this review (29). Topical or systemic administration of 5-ALA results in a selective accumulation of PPIX in neoplastic tissue, which is probably due to altered activity levels of the enzymes of the heme biosynthetic pathway within malignant transformed cells. In the protocol of Leuing et al., the patients performed a 15-minute continuous rinsing of the oral cavity using the 5-ALA solution. After an incubation period of 1 to 2.5 hours (maximum contrast after 1.5h), fluorescence investigation was performed. In 13.8% of the patients, additional findings like dysplasia, carcinoma in situ, OSCC were found through fluorescence in contrast to COE (27). An evaluation of the biopsy specimens resulted in a SP of 60% and a SE of 99% (29). ALA-induced fluorescence could represent a possible useful new diagnostic tool to detect early malignant lesions in the oral cavity. However, further studies seem to be necessary.

- Optical spectroscopy

Optical spectroscopy is a non-invasive diagnostic method that has been investigated in many forms including fluorescence spectroscopy (FS), elastic or diffuse scattering spectroscopy (ESS), and Raman spectroscopy (RS). Spectroscopic measurements can detect biochemical and architectural alterations in tissue that are related to the carcinogenesis. These alterations may include changes in the concentrations of native fluorophores such as collagen, elastin, keratin, nicotinamide adenine dinucleotide (NADH), and flavin adenine dinucleotide (FAD); changes in hemoglobin concentration and oxygenation; increasing epithelial thickness; increasing nuclear size and nuclear/cytoplasmic ratio; change in vascularization (20,25,30,31).

These principles are employed within experimental methods; SE and SP values seem to be high, but there is need for more data. Only one study for each optical spectroscopy method was identified and they had a low OEBM level (4, 3b and 2b, respectively).

References

1. Dissanyake WL, Pitiyage G, Kumarasiri PV, Liyanage RL, Dias KD, Tilakaratne WM. Clinical and histopathologic parameters in survival of oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:518-25.
2. Sciubba JJ. Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol. 2001;2:239-51.
3. Fedele S. Diagnostic aids in the screening of oral cancer. Head Neck Oncol. 2009;1:5.
4. Navone R, Burlo P, Pich A, Pentenero M, Broccolietti R, Mar- sico A, et al. The impact of liquid-based oral cytology on the diagnosis of oral squamous dysplasia and carcinoma. Cytopathology. 2007;18:356-60.
5. Mehratra R, Gupta DK. Exciting new advances in oral cancer diagnosis: avenues to early detection. Head Neck Oncol. 2011;3:33.
6. Petruzzi M, Lucchese A, Nardi GM, Lauritano D, Favia G, Ser- pico R, et al. Evaluation of autofluorescence and toluidine blue in the differentiation of oral dysplastic and neoplastic lesions from non dysplastic and neoplastic lesions: a cross-sectional study. J Biomed Opt. 2014;19:76003.
7. Kämmerer PW, Rahimi-Nedjat RK, Ziebert T, Bemsch A, Walter C, Al-Nawas B, et al. A chemiluminescent light system in combination with toluidine blue to assess suspicious oral lesions-clinical evaluation and review of the literature. Clin Oral Investig. 2015;19:459-66.
8. Pallagatti S, Sheikh S, Aggarwal A, Gupta D, Singh R, Handa R, et al. Toluidine blue staining as an adjunctive tool for early di- agnosis of dysplastic changes in the oral mucosa. J Clin Exp Dent. 2013;5:e187-91.
9. Mittal N, Palaskar S, Shankari M. Rose Bengal staining - diagnostic aid for potentially malignant and malignant disorders: a pilot study. Indian J Dent Res. 2012;23:561-4.
10. McNamara KK, Martin BD, Evans EW, Kalmar JR. The role of direct visual fluorescent examination (VELscope) in routine screening for potentially malignant oral mucosal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:636-43.
11. Awan Kh, Yang Y, Morgan P, Warnakulasuriya S. Utility of toluidine blue as a diagnostic adjunct in the detection of potentially malignant disorders of the oral cavity—a clinical and histological assessment. Oral Dis. 2012;18:728-33.
12. Mojsa I, Kaczmarzyk T, Zaleska M, Styprulwska J, Zapala-Pospiech A, Sadecki D. Value of the ViziLite Plus System as a diagnostic aid in the early detection of oral cancer/premalignant epithelial lesions. J Craniofac Surg. 2012;23:e162-4.
13. Farah CS, McIntosh L, Georgiou A, McCullough MJ. Efficacy of tissue autofluorescence imaging (VELscope) in the visualization of oral mucosal lesions. Head Neck. 2012;34:856-62.
14. Paderini C, Compilato D, Carinci F, Nardi G, Rodolico V, Lo Muzio L, et al. Direct visualization of oral-cavity tissue fluorescence as novel aid for early oral cancer diagnosis and potentially malignant disorders monitoring. Int J Immunopath Pharmacol. 2011;24(2 Suppl):121-8.
15. Awan KH, Morgan PR, Warnakulasuriya S. Utility of chemilumi- nescence (ViziLite™) in the detection of oral potentially malignant disorders and benign keratoses. J Oral Pathol Med. 2011;40:541-4.
16. Awan KH, Morgan PR, Warnakulasuriya S. Evaluation of an autofluorescence based imaging system (VELscope™) in the detection of oral potentially malignant disorders and benign keratoses. Oral Oncol. 2011;47:274-7.
17. Moro A, Di Nardo F, Boniello R, Mariantelli TM, Cervelli D, Gasparini G, et al. Autofluorescence and early detection of mu- cosal lesions in patients at risk for oral cancer. J Craniofac Surg. 2010;21:1899-903.
18. Koch FP, Kaemmerer PW, Bierfelder S, Kunkel M, Wagner W. Effectiveness of autofluorescence to identify suspicious oral lesions -a prospective, blinded clinical trial. Clin Oral Investig. 2011;15:975-82.
19. Sieroh A, Koscierz-Grzesiok A, Waskowska J, Kawczyk-Krupka A, Misiaik A, Koszowski R, et al. The role of autofluorescence diagnostics in the oral mucosa diseases. Photodiagnosis Photodyn Ther. 2008;5:182-6.
20. Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, El- Naggar AK, et al. Noninvasive evaluation of oral lesions using depth- sensitive optical spectroscopy. Cancer. 2009;115:1669-79.
21. Mallia RJ, Thomas SS, Mathews A, Kumar R, Sebastian P, Madhavan J, et al. Laser-induced autofluorescence spectral ratio reference standard for early discrimination of oral cancer. Cancer. 2008;112:1503-12.
22. Epstein JB, Silverman S Jr, Epstein JD, Lonky SA, Bride MA. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. Oral Oncol. 2008;44:538-44.
23. Du GF, Li CZ, Chen HZ, Chen XM, Xiao Q, Cao ZG, et al. Rose bengal staining in detection of oral precancerous and malignant lesions with colorimetric evaluation: a pilot study. Int J Cancer. 2007;120:1958-63.

24. Lane PM, Gilhuly T, Whitehead P, Zeng H, Poh CF, Ng S, et al. Simple device for the direct visualization of oral-cavity tissue fluorescence. J Biomed Opt. 2006;11:024006.

25. Sharwani A, Jerjes W, Salih V, Swinson B, Bigio IJ, El-Maaytah M, et al. Assessment of oral premalignancy using elastic scattering spectroscopy. Oral Oncol. 2006;42:343-9.

26. Onofre MA, Sposto MR, Navarro CM. Reliability of toluidine blue application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:535-40.

27. Leunig A, Betz CS, Mehlmann M, Stepp H, Arbogast S, Grevers G, et al. Detection of squamous cell carcinoma of the oral cavity by imaging 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Laryngoscope. 2000;110:78-83.

28. Martin IC, Kerawala CJ, Reed M. The application of toluidine blue as a diagnostic adjunct in the detection of epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:444-6.

29. Bhatia N, Matias MA, Farah CS. Assessment of a decision making protocol to improve the efficacy of VELscope™ in general dental practice: a prospective evaluation. Oral Oncol. 2014;50:1012-9.

30. Francisco AL, Correr WR, Azevedo LH, Kern VG, Pinto CA, Kowalski LP, et al. Fluorescence spectroscopy for the detection of potentially malignant disorders and squamous cell carcinoma of the oral cavity. Photodiagnostics Photodyn Ther. 2014;11:82-90.

31. Guze K, Pawluk HC, Short M, Zeng H, Lorch J, Norris C, et al. Pilot study: Raman spectroscopy in differentiating premalignant and malignant oral lesions from normal mucosa and benign lesions in humans. Head Neck. 2015;37:511-7.

32. Hanken H, Kraatz J, Smeets R, Heiland M, Assaf AT, Blessmann M, et al. The detection of oral pre-malignant lesions with an autofluorescence based imaging system (VELscope™) - a single blinded clinical evaluation. Head Face Med. 2013;9:23.

33. Rana M, Zapf A, Kuehle M, Gellrich NC, Eckardt AM. Clinical evaluation of an autofluorescence diagnostic device for oral cancer detection: a prospective randomized diagnostic study. Eur J Cancer Prev. 2012;21:460-6.

34. Cancela-Rodríguez P, Cerero-Lapiedra R, Espanar-Gómez G, Llamas-Martinez S, Warnaapusuriy S. The use of toluidine blue in the detection of pre-malignant and malignant oral lesions. J Oral Pathol Med. 2011;40:300-4.

35. Mehrottra R, Singh M, Thomas S, Nair P, Pandya S, Nigam NS, et al. A cross-sectional study evaluating chemiluminescence and autofluorescence in the detection of clinically innocuous precancerous and carcinous oral lesions. J Am Dent Assoc. 2010;141:151-6.

36. Oh ES, Laskin DM. Efficacy of the ViziLite system in the identification of oral lesions. J Oral Maxillofac Surg. 2007;65:424-6.

37. Chen YW, Lin JS, Fong JH, Wang IK, Chou SJ, Wu CH, et al. Use of methylene blue as a diagnostic aid in early detection of oral cancer and precancerous lesions. Br J Oral Maxillofac Surg. 2007;45:590-1.

38. Ram S, Siar CH. Chemiluminescence as a diagnostic aid in the detection of oral cancer and potentially malignant epithelial lesions. Int J Oral Maxillofac Surg. 2005;34:521-7.

39. Warnaapusuriy KA, Johnson NW. Sensitivity and specificity of OraScan (R) toluidine blue mouthrinse in the detection of oral cancer and precancer. J Oral Pathol Med. 1996;25:97-103.

Conflict of Interest
No conflict of interest
No financial disclosures are present for any Authors.